Priothera

Private

DublinHealthcare & Life Scienceshttps://priothera.com/

Last Round

Series B

Feb 3, 2026

Total Funding Raised

$98.27M

Company Overview

Priothera is a biotechnology company that develops S1P receptor modulators to improve outcomes for patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalmocravimodallogeneic hematopoietic stem cell transplantationallo-HCTgraft-versus-host diseaseGvHDsphingosine 1 phosphate receptor modulatorS1P receptor modulatorhematological malignanciesclinical-stage biotechdrug developmentgraft-versus-leukemiaGvLimmune modulatorclinical trialsorphan drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Priothera Comps

Public and private peers based on sector, stage, and business model.

Priothera comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Priothera Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Feb 3, 2026
Grant	Jul 11, 2025
Grant	Jun 24, 2024
Debt	Apr 4, 2022
Debt	Feb 23, 2022
Series A	Oct 12, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Florent Gros

CEO Founder

Founding Team

Priothera Investors

Notable investors and investment history

Priothera investors
Investor	Rounds
4see ventures	Series B
Bpifrance	Grant, Debt
Fountain Healthcare Partners	Series B, Series A
HealthCap	Series B, Series A
European Investment Bank Group	Debt
Tekla Capital Management	Series A
Earlybird Venture Capital	Series B, Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jun 24, 2025
$2M grant round led by Bpifrance.
Jun 3, 2025
Dr. Hans Menssen appointed to the Board of Directors.

View all signals

Priothera Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Priothera Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Priothera's valuation, stock price, and market status.

Firmographic Details

HeadquartersDublin

Employee Range26

Year Founded2020

Last FundingFeb 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.